NO933897L - HBV-overflateproteiner med redusert vertskarbohydrat - Google Patents

HBV-overflateproteiner med redusert vertskarbohydrat

Info

Publication number
NO933897L
NO933897L NO933897A NO933897A NO933897L NO 933897 L NO933897 L NO 933897L NO 933897 A NO933897 A NO 933897A NO 933897 A NO933897 A NO 933897A NO 933897 L NO933897 L NO 933897L
Authority
NO
Norway
Prior art keywords
hbv
surface proteins
particles
hbv surface
substantially reduced
Prior art date
Application number
NO933897A
Other languages
English (en)
Norwegian (no)
Other versions
NO933897D0 (no
Inventor
Peter J Kniskern
Arpi Hagopian
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO933897D0 publication Critical patent/NO933897D0/no
Publication of NO933897L publication Critical patent/NO933897L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/02Hepadnaviridae, e.g. hepatitis B virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
NO933897A 1991-04-29 1993-10-28 HBV-overflateproteiner med redusert vertskarbohydrat NO933897L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69292491A 1991-04-29 1991-04-29
PCT/US1992/003472 WO1992019741A1 (en) 1991-04-29 1992-04-27 Hbv virus surface proteins with reduced host carbohydrate

Publications (2)

Publication Number Publication Date
NO933897D0 NO933897D0 (no) 1993-10-28
NO933897L true NO933897L (no) 1993-10-28

Family

ID=24782605

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933897A NO933897L (no) 1991-04-29 1993-10-28 HBV-overflateproteiner med redusert vertskarbohydrat

Country Status (25)

Country Link
US (1) US5614384A (es)
EP (1) EP0516286B1 (es)
JP (1) JP2637877B2 (es)
KR (1) KR920019373A (es)
CN (1) CN1067680A (es)
AT (1) ATE215987T1 (es)
AU (1) AU650530B2 (es)
BG (1) BG61700B1 (es)
CA (1) CA2067290A1 (es)
CZ (1) CZ282769B6 (es)
DE (1) DE69232541D1 (es)
FI (1) FI934650A (es)
HU (1) HUT69149A (es)
IE (1) IE921385A1 (es)
IL (1) IL101651A0 (es)
LT (1) LT3367B (es)
MX (1) MX9201970A (es)
NO (1) NO933897L (es)
NZ (1) NZ242487A (es)
PL (1) PL171485B1 (es)
SG (1) SG55152A1 (es)
SK (1) SK118193A3 (es)
WO (1) WO1992019741A1 (es)
YU (1) YU45492A (es)
ZA (1) ZA923069B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533263A3 (en) * 1991-09-20 1994-06-08 Merck & Co Inc A multivalent hepatitis b virus vaccine
YU30495A (sh) * 1994-05-16 1997-12-05 Merck & Co. Inc. Postupak za dobijanje hbv površinskih proteina
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
AU2212100A (en) * 1998-12-23 2000-07-12 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen
KR100604994B1 (ko) 2004-01-30 2006-07-26 한국생명공학연구원 알파1,6-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자 및 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법
CN111187720A (zh) * 2019-12-27 2020-05-22 深圳康泰生物制品股份有限公司 表达肠道病毒71型抗原的重组汉逊酵母的细胞破碎方法及其在制备手足口病疫苗中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
US4707542A (en) * 1983-08-22 1987-11-17 Merck & Co., Inc. Immunogenic HbsAg derived from transformed yeast
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
GB8613388D0 (en) * 1986-06-03 1986-07-09 Delta Biotechnology Ltd Induction of galactose regulated gene expression in yeast
DE3719213C1 (de) * 1987-06-09 1988-05-19 Daimler Benz Ag Bodennahe mehrpolige Stromversorgung fuer spurfuehrbare,gummibereifte,elektrisch antreibbare Fahrzeuge
US4963483A (en) * 1987-10-13 1990-10-16 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US5135854A (en) * 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
EP0314096B1 (en) * 1987-10-29 1994-01-12 Zymogenetics, Inc. Methods of regulating protein glycosylation
GB8726953D0 (en) * 1987-11-18 1987-12-23 Delta Biotechnology Ltd Yeast expression system
NZ229260A (en) * 1988-06-03 1994-02-25 Merck & Co Inc Hepatitis b virus, expression cassette for pre-s domain, host cells and
ES2109921T3 (es) * 1989-07-25 1998-02-01 Smithkline Beecham Biolog Nuevos antigenos y procedimientos para su preparacion.
CA2022109A1 (en) * 1989-07-31 1991-02-01 Cheryl A. Schulman Enhanced expression of heterologous proteins in recombinant hosts in a non-growth media
CA2022108A1 (en) * 1989-07-31 1991-02-01 Cheryl A. Schulman Enhanced growth and expression of heterologous proteins in recombinant hosts containing mutations in cell wall and/or plasma membrane biosynthesis
EP0431679B1 (en) * 1989-12-05 1994-10-19 Merck & Co. Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from yeast
IL101653A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Multiple hepatitis b virus surface proteins which form particles

Also Published As

Publication number Publication date
CA2067290A1 (en) 1992-10-30
BG61700B1 (bg) 1998-03-31
JPH06141872A (ja) 1994-05-24
EP0516286A1 (en) 1992-12-02
IL101651A0 (en) 1992-12-30
NO933897D0 (no) 1993-10-28
IE921385A1 (en) 1992-11-04
LTIP462A (en) 1994-10-25
CZ282769B6 (cs) 1997-10-15
SG55152A1 (en) 1998-12-21
KR920019373A (ko) 1992-11-19
WO1992019741A1 (en) 1992-11-12
CN1067680A (zh) 1993-01-06
HUT69149A (en) 1995-08-28
ATE215987T1 (de) 2002-04-15
AU650530B2 (en) 1994-06-23
BG98187A (bg) 1994-06-30
SK118193A3 (en) 1994-03-09
CZ227193A3 (en) 1994-04-13
LT3367B (en) 1995-08-25
HU9303064D0 (en) 1994-03-28
ZA923069B (en) 1992-12-30
DE69232541D1 (de) 2002-05-16
MX9201970A (es) 1992-11-01
US5614384A (en) 1997-03-25
FI934650A0 (fi) 1993-10-21
YU45492A (sh) 1994-06-10
JP2637877B2 (ja) 1997-08-06
FI934650A (fi) 1993-10-21
AU1522292A (en) 1993-03-11
NZ242487A (en) 1994-07-26
PL171485B1 (pl) 1997-05-30
EP0516286B1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
ATE302795T1 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus hüllproteine
NO933897D0 (no) Hbv-overflateproteiner med redusert vertskarbohydrat
DE69333057D1 (de) Rekombinente Adenoviren-Impfstoffe
YU45292A (sh) Različiti površinski proteini hepatitis b virusa koji obrazuju čestice
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
CA2116355A1 (en) Infectious bovine rhinotracheitis virus mutants and vaccines
NZ295056A (en) Hepatitis virus e strain, recombinant proteins thereof, use in diagnostic methods and vaccines
DZ1550A1 (fr) Vaccin depourvu de cellules contre le virus de la maladie marek.
CA2105277A1 (en) Genetically engineered vaccine strain
EP0288198A3 (en) Production of peptide
RU93058279A (ru) Система экспрессии, белок, вакцина, реагент
DK257887D0 (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
EP0485347A3 (en) Recombinant hepatitis delta antigen, process for the purification and use thereof
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
YU30495A (sh) Postupak za dobijanje hbv površinskih proteina
RU93057939A (ru) Вакцина против парвовирусного энтерита и чумы собак, способ ее изготовления и способ профилактики

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application